

Malta, 25 January 2008

Circular No. P03/2008

Dear Healthcare Professional,

Re: New warnings and contraindications for rosiglitazone

The Committee for Medicinal Products for Human Use (CHMP) has adopted two new scientific opinions regarding rosiglitazone to include new warnings stating that the use of rosiglitazone in patients with ischemic heart disease and/or peripheral arterial disease is not recommended, and to add a contra-indication in patients with acute coronary syndrome. The Medicines Authority has participated in these discussions held at the European Medicines Agency (EMA) and is in agreement with the [press release](#) and [Q&A document](#) issued by the EMA, attached here for your perusal.